Tocilizumab is a Monoclonal Antibody owned by Chugai Pharmaceutical, and is involved in 320 clinical trials, of which 252 were completed, 61 are ongoing, and 7 are planned.

Tocilizumab is interleukin-6 (IL-6) receptor antagonist. It binds specifically to both soluble and membrane-bound interleukin-6 (IL-6) receptors (sIL-6R and mIL-6R). Actemra has been shown to inhibit sIL-6R and mIL-6R-mediated signalling. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, monocytes and fibroblasts. IL-6 is involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, induction of hepatic acute phase protein synthesis and stimulation of haemopoiesis.

The revenue for Tocilizumab is expected to reach a total of $16.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tocilizumab NPV Report.

Tocilizumab was originated by Osaka University and Chugai Pharmaceutical and is currently owned by Chugai Pharmaceutical. F. Hoffmann-La Roche is the other company associated in development or marketing of Tocilizumab.

Tocilizumab Overview

Tocilizumab (Actemra / Roactemra) is a humanized monoclonal antibody, acts as immunosupressant preparation. It is formulated as injectable solution and solution concentrate for intravenous or subcutaneous route of administration. Actemra is indicated for the treatment of rheumatoid arthritis in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease modifying anti-rheumatic drugs via intravenous and subcutaneous route. Tocilizumab intravenous route is indicated for the treatment of polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis in patients of 2 years age and older. Roactemra, in combination with methotrexate (MTX), is indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX. It is also indicated to treat adults with temporal arteritis, takayasu arteritis, and vasculitis, for the treatment of cytokine release syndrome induced by tumor-specific T cell infusion therapy. Actemra (tocilizumab) is used as emergency treatment for coronavirus disease 2019 (COVID-19) in hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Actemra is indicated for the treatment of pneumonia caused by SARS-CoV-2

The drug candidate is under development for the treatment of follicular lymphoma, metastatic hepatocellular carcinoma, non-small cell lung cancer, systemic sclerosis large-vessel vasculitis, giant cell arteritis, polymyalgia rheumatica, Behcet’s Uveitis, granulomatosis with polyangiitis, Schnitzler syndrome, pain, familial mediterranean fever and diffuse large b-cell lymphoma. It is also under development for COVID-19 pneumonia and in hospitalized adult patients with severe COVID-19. It was also under development for the treatment of idiopathic retroperitoneal fibrosis, pulmonary arterial hypertension, Grave's orbitopathy or thyroid eye disease, ankylosing spondylitis, giant lymph node hyperplasia and metastatic pancreatic cancer, polymyositis, dermatomyositis, amyotrophic lateral sclerosis and B-Cell Chronic Lymphocytic Leukemia.

F. Hoffmann-La Roche Overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.

Quick View – Tocilizumab

Report Segments
  • Innovator (NME)
Drug Name
  • Tocilizumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Immunology
  • Infectious Disease
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Oncology
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.